Product Information
SPRYCEL 100 MG TABLET is a brand product labeled by E.R. Squibb & Sons, L.L.C., priced at $591.1812 per EA under NDC 00003085222. Its NADAC has been published 659 times since Nov 28, 2013.
FDA first approved this application on Jun 28, 2006. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the dasatinib market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
100 mg/1
Manufacturer
E.R. Squibb & Sons, L.L.C.NDC
00003085222
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
5/20/2026
Active Ingredients
DASATINIBApproval Type
New Drug (NDA)
FDA Application
NDA021986FDA Approved
6/28/2006
TE Code
AB
On Market Since
5/30/2008
Pharmacological Classes
Price Statistics
The NADAC for SPRYCEL 100 MG TABLET has been published 659 times since Nov 28, 2013, and over the history we have for it it has risen 103.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $591.1812 per EA |
|---|---|
| All-time high | $591.4984 (Jul 16, 2025) |
| All-time low | $283.1137 (Dec 18, 2013) |
| 52-week high | $591.1812 |
| 52-week low | $590.4716 |
| Median price | $466.0697 |
| Average price | $455.0010 |
| Largest weekly change | +7.5% (Mar 25, 2015) |
| Weeks tracked | 659 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 96% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
E.R. Squibb & Sons, L.L.C. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
dasatinib market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Kinase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SPRYCEL 100 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for SPRYCEL 100 MG TABLET, manufactured by E.R. Squibb & Sons, L.L.C., is $591.1812 per EA (NDC 00003085222), effective Sep 30, 2026.
How has the price of SPRYCEL 100 MG TABLET changed over time?
Over the history we have for it, the NADAC for SPRYCEL 100 MG TABLET has risen 103.9%. It has been tracked across 659 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for SPRYCEL 100 MG TABLET?
Since Nov 28, 2013, the NADAC for SPRYCEL 100 MG TABLET has ranged from a low of $283.1137 (Dec 18, 2013) to a high of $591.4984 (Jul 16, 2025), with a median of $466.0697 per EA.
Are there cheaper alternatives to SPRYCEL 100 MG TABLET?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, DASATINIB 100 MG TABLET, is $26.4568 per EA — about 96% below SPRYCEL 100 MG TABLET.
Who manufactures SPRYCEL 100 MG TABLET?
SPRYCEL 100 MG TABLET (NDC 00003085222) is labeled by E.R. Squibb & Sons, L.L.C., and CMS classifies it as a brand product.